Abstract

Bone cancer and metastasis need new knowledge and pathogenesis insights. Plenty of cancer patients with osteosarcoma and cancer metastasis show great pain and low survival intervals. Facing critical challenge of bone-related cancer, disease diagnosis and treatment needs improved and cutting-edge techniques. To improve patient’s treatment, overall situations and sustainable medication should be focused in this editorial.

Keywords:Bone Cancer; Neoplasm Metastasis; Drug Treatment; Clinical Diagnosis; Bone Tumor

Introduction

Cancer is the secondary leading mortality for all diseases worldwide. Neoplasm metastasis plays leading role for patient’s deaths [1-4]. Bone cancer and metastasis need new knowledge and pathogenesis insights. A lot of cancer patients with osteosarcoma and cancer metastasis show great pain and low survival intervals. Facing critical challenge of bone-related cancer, disease diagnosis and treatment needs improved and cutting-edge techniques. To improve patient’s treatment, overall situations and sustainable medication should be focused [5]. Human bone tissue is one of common tissues for metastatic tumor outgrowths [5-8]. To avoid devastating features of bone cancer and metastasis, pathogenesis and diagnostic relations should be boosted, especially in areas of drug treatment studies.

Clinical Treatment Studies

There are a lot of different anticancer drugs in the clinic. At present, drug treatment and combinations are first choice. To accelerate this research, drug response predictions in the clinic is modern and challenging and should be placed on the high agenda [9-16]; In experimental study, we can receive data of drug responses from animals. Clinical diagnostics is difficult for evaluation of drug responses due to unstable of diagnostic profiles, especially in image evaluations. Blood circulatory tumors or their biomarkers are new hopes for therapeutic selection and successes [9-13]. These diagnostic and management tools should be developed.

Diagnostic Progress

Drug treatment for metastatic diseases has different categories [3]. The association and relationship between diagnosis and drug responses should be built in the future. Personalized medicine and precision oncology is a useful drug selection paradigm and, in the future, [17-24]. This emerging medical ideas, techniques, and system is progressing rapidly [25-33]. Future advancement in this issue should be greatly expected, especially from traditional medicine [34].

Conclusion

Clinical cancer diagnostic study should focus on technical advances. New knowledge and technology should be introduced. Many new discoveries can be found via above-mentioned approaches.

References

1. Lambert, AW, Pattabiraman DR, Weinberg RA (2017) Emerging biological principles of metastasis. Cell 168: 670-691
2. Ahmad AS, Ormisten-Smith N, Sasienip D (2015) Trends in the lifetime risk of developing cancer in Great Britain; Comparison of risk for those born from 1930-1960. Br J Cancer 112(5): 943-947.
3. Lu DY, Lu TR (2025) Antimetastatic drugs, pharmacologic challenge and opportunity. Current Drug Therapy 20(2): 169-179.
4. Gerstberger S, Jiang Q, Ganesh K (2023) Metastasis. Cell 186(8): 1564-1579
5. Lu DY, Xu B (2021) Bone metastasis treatment, major frontiers. Acta Scientific Orthopaedics 4(7): 1-2.
6. Hakim BAA (2021) Benign bone tumors, an overview. Acta Scientific Orthopaedics 4(10): 1-2.
7. Lu DY, Xu B (2021) Bone cancer and metastatic trials, drug treatment. Acta Scientific Orthopaedics 4(9): 31-33.
8. Lu DY, Lu TR, Wu HY, Cao S (2013) Cancer Metastasis treatments. Current Drug Therapy 8(1): 24-29.
9. Bhadresha KP, Patel M, Jain NK, Rawal RM (2021) A predictive biomarker panel for bone metastasis, liquid biopsy approach. J Bone Oncology 29: 100371
10. Pantel K, Alix-Panabieres C (2022) Crucial roles of circulating tumor cells in the metastatic cascade and tumor immune escape: biology and clinical translation. J Immuno Therapy of Cancer 10(12): e005615.
11. Lu DY (2026) Advances in cancer therapeutics and genomics for improved patient outcomes. Current Cell Science 1: 43-46.
12. Lu DY, Lu TR (2025) Cancer bioinformatics, new chapter of personalized medicines. Journal of Internal Medicine and Health Affairs 4(1): 044.
13. Lu DY, Che JY (2026) Bone tumors and metastasis, diagnostic promotion. EC Orthopaedics 17(1): 1-3.
14. Lu DY, Che JY (2025) Possible ways of bone pain alleviation. EC Orthopedics 16(5): 1-4.
15. Lu DY, Xu B (2022) Cancer bone metastasis, experimental study. Acta Scientific Orthopeadics 5(12): 1-3.
16. Lu DY, Lu TR, Xu B, Che JY, Wu SY, et al. (2018) Anti-metastatic drug development, work out towards new direction. Medicinal Chemistry 8 (7): 192-196.
17. Lu DY, Lu TR, Yarla NS, Xu B (2022) Drug sensitivity testing for cancer therapy, key areas. Reviews on Recent Clinical Trials 17(4): 291-299.
18. Volm M, Efferth T (2015) Prediction of cancer drug resistance and implications for personalized medicine. Frontiers in Oncology 5: 282.
19. Lu DY, Lu TR (2020) Drug sensitivity testing, a unique drug selection strategy. Advances in Biomarker Sciences and Technology 2: 59-66.
20. Lu DY, Qi RX, Lu TR, Wu HY (2017) Cancer bioinformatics for update anticancer drug developments and personalized therapeutics. Reviews on Recent Clinical Trials 12(2): 101-110.
21. Montero J, Sarosiek KA, DeAngels JD, Maertens O, Ercan D, et al. (2015) Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell 160(5): 977-989.
22. Popova AA, Levkin PA (2020) Precision medicine in oncology: In vitro drug sensitivity and resistance test (DSRT) for selection of personalized anticancer therapy. Adv Therapeutics. 1900100.
23. Zhang Y, Xu J, Yu Y, Shang W, Ye A (2018) Anticancer drug sensitivity assay with quantitative heterogeneity testing using single-cell Raman Spectroscope. Molecules 23 (11): 2903.
24. Wang JK, Lin KC, Hu HJ, Qie XW, Huang WE, et al. (2021) In vitro anticancer drug sensitivity sensing through single-cell Raman Spectroscopy. Biosensors 11(8): 286.
25. Pantano F, Croset M, Driouch K, Bednarz-Knoll N, Iuliani M, et al. (2021) Integrin alpha 5 in human breast cancer is a mediator of bone metastasis and a therapeutic target for the treatment of osteolytic lesions. Oncogene 40(7): 1284-1299.
26. Lu DY, Che JY (2021) Bone disease treatments, importance of technical supports. Acta Scientific Orthopaedics 4(4): 55-57.  
27. Lu DY, Lu TR (2025) Personalized oncology: scientific and technical approaches. Current Cell Science 1(1): 57-66.
28. Lu DY, Lu TR, Che JY, Shen Y, Yarla NS (2018) Individualized cancer therapy, future approaches. Current Pharmacogenomics & Personalized Medicine 16 (2): 156-163
29. Barani M, Mukhtar M, Rahdar A, Sargazi S, Pandey S, et al. (2021) Recent advances in nanotechnology-based diagnosis and treatments of human osteosarcoma. Biosensors 11(2): 55.
30. Lu DY, Putta S, Che JY (2023) Bone metastasis and circulation biomarkers profiling toward personalized cancer medicine. BME Horizon 1 (3): 91.
31. Lu DY, Che JY (2023) Bone metastasis diagnosis, blood biomarker detections. Biomed J Sci Tech Res 52(4): 8276.
32. Elshimy Y, Alkhatib AR, Atassi B, Mohammad KS (2025) Biomarker-driven approaches to bone metastasis: from molecular mechanisms to clinical applications. Biomedicine 13: 1160.
33. Lu DY, Lu TR (2025) Cancer bioinformatics, new chapter of personalized medicines. Journal of Internal Medicine and Health Affairs 4(1).
34. Lu DY, Lu TR (2025) Traditional medicine, drug and clinical development. Clinical & Medical Microbiology 1(1): 1-12.